FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients

Current status of chemotherapy for the treatment of advanced biliary tract cancer

(2013) Takashi Sasaki et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

(2011) Jun Ho Yi et al.   EUROPEAN JOURNAL OF CANCER

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

(2010) T Okusaka et al.   BRITISH JOURNAL OF CANCER

Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma

(2010) Philippe A. Cassier et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness

(2010) Sung Yong Oh et al.   INVESTIGATIONAL NEW DRUGS

Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer

(2010) Takashi Sasaki et al.   INVESTIGATIONAL NEW DRUGS

Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study

(2010) Atul Sharma et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

(2010) Jochen Weigt et al.   Expert Review of Gastroenterology & Hepatology

A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma

(2009) Jen-Shi Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial

(2008) O Nehls et al.   BRITISH JOURNAL OF CANCER